ArticleCancer management and research2026
Tumor-Derived Exosomal PDLIM1 Promotes Angiogenesis and Tumor Progression in Papillary Thyroid Carcinoma: Insights From Integrated Single-Cell Transcriptomics and Exosomal Proteomics.
Article in Cancer management and research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Cell-state transitions and microenvironmental remodeling in thyroid cancer progression revealed by single-cell and spatial transcriptomics.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Papillary thyroid carcinoma (PTC) with metastatic potential presents a complex and poorly understood tumor microenvironment. Despite its clinical significance, the cellular and molecular mechanisms driving metastatic progression remain inadequately characterized, particularly the role of intercellular communication mediated by tumor-derived exosomes. Methods: We analyzed single-cell RNA sequencing (scRNA-seq) on primary and metastatic PTC tissues (n=12 samples from 4 patients), exploring cellular heterogeneity and distinct subpopulations. Metastasis-associated cell states (Scissor+ and Scissor-) were delineated using the Scissor algorithm. Pathway activity in these subpopulations was analyzed using the PROGENy algorithm.Exosomal proteomic data from lymph node metastasis patients were cross-referenced with Scissor+ signatures, identifying candidate proteins. Functional validation included in vitro angiogenesis assays with HUVECs and in vivo xenograft models to assess tumor growth and vascularization. Results: ScRNA-seq revealed significant tumor cell heterogeneity between primary and metastatic sites, with Scissor+ cells strongly linked to metastatic phenotypes. PROGENy analysis demonstrated significant upregulation of VEGF signaling in Scissor+ cells. Among six key proteins identified, PDLIM1 was highly expressed in PTC cell lines and metastatic tissues (P < 0.001). Tumor-derived exosomal PDLIM1 was internalized by endothelial cells, enhancing angiogenesis in vitro. PDLIM1 knockdown in exosomes suppressed HUVEC tube formation (P < 0.05) and reduced tumor volume, CD31+ microvessel density, and LYVE-1+ lymphatic vessel density in xenografts (P < 0.05). Conclusion: Our study suggests that exosomal PDLIM1 may play a role in promoting angiogenesis and primary tumor progression in PTC. These findings provide preliminary insights into the potential involvement of exosome-mediated intercellular communication in PTC pathogenesis. Further validation in larger cohorts and functional studies, including rescue experiments, are warranted to evaluate whether targeting PDLIM1 could represent a viable therapeutic strategy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.